Skip to content

A clinical study on regulating IL6/STAT3 signaling pathway based on "Xuanfu-Sweat Gland" by applying Ma Dou Can No.1 formula for the treatment of damp-heat-embedded skin-type psoriasis of common type

A clinical study on regulating IL6/STAT3 signaling pathway based on "Xuanfu-Sweat Gland" by applying Ma Dou Can No.1 formula for the treatment of damp-heat-embedded skin-type psoriasis of common type

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001029
Enrollment
Unknown
Registered
2025-05-26
Start date
2024-10-25
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

treatment group:Ma Dou Can No.1 formula.urea ointment
control subjects:Avitamin A Capsules.urea ointment

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the western medical diagnostic criteria for psoriasis drawn up with reference to the China Psoriasis Diagnostic and Treatment Guidelines (2023 edition) and Dermatology and Venereology (9th edition edited by Zhang Xuejun and Zheng Jie) and also meet the Chinese medical diagnostic criteria for the dampness-heat-impregnated-skin-type leukoderma plagiosum drawn up by the Expert Consensus on Traditional Chinese Medicine Treatment of Psoriasis of Dermatology Sub-Committee (2017 edition); (2) 18 years old = age = 70 years old; (3) Not using immunosuppressive topical preparations such as glucocorticoids in the past week; (4) Have not systematically taken immunosuppressants such as methotrexate Avitamin A or injections of biologics such as stavudine adalimumab etc. in the past 3 months; (5) Subjects who have completed the informed consent form and voluntarily participate in this study;

Exclusion criteria

Exclusion criteria: (1) Subjects who are unconscious or suffering from mental illness or who do not have civil capacity; (2) Subjects with hepatic or renal insufficiency especially those who suffer from cardiovascular cerebrovascular hematopoietic system and other serious primary diseases in combination; (3) Subjects with autoimmune diseases malignant tumors and/or other serious consumptive diseases easily combined with infections and bleeding;

Design outcomes

Primary

MeasureTime frame
PASI ;

Secondary

MeasureTime frame
DLQI;mRNA of peripheral blood STAT3, IL-6;VAS ;HAMD;

Countries

China

Contacts

Public Contactchenmingling

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

cmlll388@sina.com+86 139 0822 2682

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026